Is IRADIMED CORPORATION (IRMD) Overvalued?
We dive into why IRADIMED CORPORATION (IRMD) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.
Commentary & Analysis
What You Need to Know About IRADIMED CORPORATION's Q3 Earnings
IRADIMED CORPORATION's fiscal Q3 earnings report was released on Friday, July 31. Let's dive in to see if (IRMD) missed or beat analyst's expectations.Jenna Brashear
Why IRADIMED CORPORATION’s (IRMD) Stock Is Down 5.26%
As of Friday, May 01, IRADIMED CORPORATION’s IRMD share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Michael Rose
What You Need to Know About IRADIMED CORPORATION's Q2 Earnings
IRADIMED CORPORATION's fiscal Q2 earnings report was released on Friday, May 01. Let's dive in to see if (IRMD) missed or beat analyst's expectations.Tudor Pop
Why IRADIMED CORPORATION’s (IRMD) Stock Is Up 12.43%
As of Tuesday, February 10, IRADIMED CORPORATION’s IRMD share price has surged by 12.43%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | IRMD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,127.9 | $417.6 | 47% |
|
| Shares Out (Mil) | 12.9 | 41.2 | 24% |
|
| Institutional Ownership | 64.5% | 83.3% | 40% |
|
| Float (Mil) | 8.3 | 35.9 | 17% |
|
| Beta | 0.90 | 0.85 | 54% |
|
| Avg Daily Volume (000s) | 96 | 274 | 36% |
|
| Price Change (52-week) |
20.1% | 62.8% | 68% |
|
| Growth | IRMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 21.5% | 11.8% | 83% |
|
| Net Income (5yr) | 74.3% | (4.8%) | 97% |
|
| EPS (5yr) | 73.9% | 10.6% | 98 |
|
| Dividends (5yr) | 0.0% | 0.0% | 75% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.550 | $2.113 | $2.453 | |
| Month Ago EPS | $0.545 | $2.090 | $2.410 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | $0.540 | $2.075 | $2.355 | |
| Year/Year Chg | 34.8% | 20.7% | 55.1% | |
| Financials | IRMD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $86 | $155 | 25% |
|
| Net Income (TTM) (Mil) | $23 | ($9) | 50% |
|
| EPS (TTM) | $1.807 | ($0.400) | 69% |
|
| Operating Cash Flow (TTM) (Mil) | $27 | ($2) | 43% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $1 | 53% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $28 | 0% |
|
| Enterprise Value (Q1) (Mil) | $991 | $437 | 41% |
|
| Valuation | IRMD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 11.08 | 2.52 | 92% |
|
| P/E | 49.3 | 26.7 | 85% |
|
| Dividend Yield | 0.9% | 0.0% | 66% |
|
| PEG (5yr hist) | 0.7 | 1.5 | 34% |
|
| Ratios | IRMD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.9% | 59.0% | 86% |
|
| Net Margin | 26.7% | (6.9%) | 85% |
|
| ROA | 20.8% | (12.2%) | 96% |
|
| ROE | 23.5% | (10.5%) | 83% |
|
| Liabilities to Assets | 11.5% | 47.2% | 7% |
|
| F-Score | 4 | 4 | 33% |
|
Passing Stock Screens
As of 10/20/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Buffettology: EPS Growth
Factors: Quality, Growth
Buffett approach seeking consumer monopolies selling at a reasonable price.
| Performance Since Inception: | 12.2% |
| +/- S&P 500: | +4.7 |
